About: Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic
Creator	Meijer, Adam Kuijpers, Judith Goderski, Gabriel Wijsman, Lisa Melchers, Willem Van Den Brink, Sharon Overdevest, Ilse Broeders, Maaike Chung, Ngoc Favié, Barbara Rahamat-Langedoen, Janette Van De Bovenkamp, Jeroen Van Den Bosch, Bart Wolters, Femke
Source	Elsevier; Medline; PMC; WHO
abstract	BACKGROUND: With the outbreak of SARS-CoV-2, rapid diagnostics are paramount to contain the current pandemic. The routinely used realtime RT-PCR is sensitive, specific and able to process large batches of samples. However, turnaround time is long and in cases where fast obtained results are critical, molecular point of care tests (POCT) can be an alternative. Here we report on a multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2 point-of-care test. STUDY DESIGN: The Xpert Xpress SARS-CoV-2 assay was evaluated against the routine in-house real-time RT-PCR assays in three medical microbiology laboratories in The Netherlands. A sensitivity and specificity panel was tested consisting of a dilution series of SARS-CoV-2 and ten samples containing SARS-CoV-2 and a range of other seasonal respiratory viruses. Additionally, 58 samples of patients positive for SARS-CoV-2 with different viral loads and 30 tested negative samples in all three Dutch laboratories using an in-house RT-PCR, were evaluated using Cepheids Xpert Xpress SARS-CoV-2 cartridges. RESULTS: Xpert Xpress SARS-CoV-2 point of care test showed equal performance compared to routine in-house testing with a limit of detection (LOD) of 8.26 copies/mL. Other seasonal respiratory viruses were not detected. In clinical samples Xpert Xpress SARS-CoV-2 reaches an agreement of 100 % compared to all in-house RT-PCRs CONCLUSION: Cepheids GeneXpert Xpert Xpress SARS-CoV-2 is a valuable addition for laboratories in situations where rapid and accurate diagnostics are of the essence.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104426
bibo:pmid	32417674
has license	no-cc
sha1sum (hex)	b774f598b90bc04d00ce3c0fcb997b0d3d33b826
schema:url	https://doi.org/10.1016/j.jcv.2020.104426
resource representing a document's title	Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic
has PubMed Central identifier	PMC7211760
has PubMed identifier	32417674
schema:publication	J Clin Virol
resource representing a document's body	covid:b774f598b90bc04d00ce3c0fcb997b0d3d33b826#body_text
is schema:about of	named entity 'assays' named entity 'SARS-CoV-2' named entity 'compared' named entity 'evaluated' named entity 'cartridges' named entity 'laboratories' named entity 'SARS-CoV-2' named entity 'evaluation' named entity 'pandemic' named entity 'Cepheid' named entity 'OBTAINED' named entity 'EQUAL' named entity 'VIRAL' named entity 'DIAGNOSTICS' named entity 'PANDEMIC' named entity 'EVALUATION' covid:arg/b774f598b90bc04d00ce3c0fcb997b0d3d33b826 named entity 'SARS-CoV-2' named entity 'laboratories' named entity 'cases' named entity 'fast' named entity 'panel' named entity 'SARS-CoV-2' named entity 'current' named entity 'viruses' named entity 'Xpress' named entity 'SARS-CoV-2' named entity 'point-of-care test' named entity 'SARS-CoV-2' named entity 'point of care' named entity 'LOD' named entity 'assay' named entity 'Dutch' named entity 'clinical samples' named entity 'Cepheid' named entity 'viruses' named entity 'Xpert Xpress' named entity 'point-of-care test' named entity 'samples' named entity 'RT-PCR' named entity 'SARS-CoV-2' named entity 'Upper respiratory tract' named entity 'Point-of-Care testing' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Digital PCR' named entity 'plastics' named entity 'quality assessment' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'RNA' named entity 'PCR' named entity 'transport medium' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'clinical samples' named entity 'turnaround time' named entity 'Xpert Xpress' named entity 'freeze-thaw' named entity 'PCR' named entity 'gene' named entity 'RNA' named entity 'molecular diagnostics' named entity 'Xpert Xpress' named entity 'RdRp' named entity 'gene' named entity 'gene'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software